Intestinal Immune Response in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Intestinal Immune Response in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
批准号:
9206443
负责人:
ARMIN ALAEDINI
金额:
$24.0万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-01-15 至 2018-05-31
关键词:
AffectAgeAntibodiesAntibody ResponseAntigenic SpecificityApplications GrantsBiological MarkersCD14 geneCeliac DiseaseCerealsChronic Fatigue SyndromeControlled StudyDataDefectDevelopmentDiagnosisDietDiseaseEconomic BurdenElectrophoresisEndotoxinsEnzymesEpitope MappingEpitopesEtiologyExhibitsFunctional disorderGenderGliadinGlutenHeterogeneityImmuneImmune responseImmune systemImmunoblottingImmunoglobulin AImmunoglobulin GImmunoglobulin MImmunologicsIndividualInflammationIntestinesMapsMass Spectrum AnalysisMediatingMolecular TargetMucosal Immune ResponsesNIH Program AnnouncementsPathogenesisPatientsPatternPlasmaProteinsProteomeProteomicsPublishingReportingRequest for ApplicationsRiskRoleSamplingSerum amyloid A proteinSeveritiesSpecificitySymptomsTimeTreatment outcomeWheatWomancohortdisease phenotypeexperimental studygastrointestinal symptomgluteninimmunoreactivitylipopolysaccharide-binding proteinmicrobialmicroorganism antigennovelnovel markerpatient subsetspublic health relevanceresponse biomarkerspecific biomarkerstandem mass spectrometrytransglutaminase 2treatment strategytwo-dimensional
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A major barrier to a better understanding of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been the heterogeneity within the condition and the lack of biomarkers to characterize disease phenotypes and analyze treatment outcome. While the etiology and pathogenesis of ME/CFS are poorly understood, there is evidence that immune system abnormalities are associated with symptoms in a substantial number of affected individuals. In addition, many ME/CFS patients complain of gastrointestinal (GI) symptoms of unknown etiology. However, immune responses to dietary and microbial antigens as underlying causes of the reported GI symptoms or as contributors to systemic inflammation have not been explored in controlled studies. Our preliminary data from a study of well-characterized patients and controls demonstrate that individuals with ME/CFS exhibit significantly elevated antibody reactivity to gluten, which correlates with the severity of GI symptoms. Moreover, the results show that the observed immune response to gluten in ME/CFS is fundamentally distinct from that in celiac disease, being independent of the action of transglutaminase 2 enzyme and HLA-DQ2/DQ8 molecules. Additional data within this application indicate that increased antibody reactivity to gluten can be associated with microbial translocation in individuals without celiac disease. We hypothesize that the molecular targets of the antibody response to gluten in ME/CFS are unique, further characterization of which may identify novel biomarkers of the condition, and that this immune response is associated with microbial translocation and systemic inflammation in a subset of ME/CFS patients. To analyze the molecular targets of the identified immune reactivity and assess its implications for ME/CFS, we propose two specific aims. In Aim 1, we will map the antigenic specificity of the immune response to gluten in ME/CFS through mass spectrometry-assisted proteome analysis and epitope mapping. In Aim 2, we will assess the relationship between the immune response to gluten and specific markers of microbial translocation and systemic inflammation in ME/CFS. The information that is expected to emerge if the aims of the proposed project are achieved would 1) offer biomarkers that may be useful in identifying subsets of patients or individuals at risk of developing ME/CFS, 2) support the examination of specific treatment strategies targeted at the identified subset of patients, and 3) yield experimental support for closer examination of the role of intestinal barrier defects and aberrant mucosal immune response in the pathophysiology of ME/CFS. This grant proposal is in line with the program announcement's (PAR-12-033) request for applications that "examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome", such as the identification "of environmental, including dietary, precipitants" and the development of "novel and objective biological markers for the diagnosis of ME/CFS".
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
C-Reactive Protein Response in Patients With Post-Treatment Lyme Disease Symptoms Versus Those With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
莱姆病治疗后症状患者与肌痛性脑脊髓炎/慢性疲劳综合症患者的 C 反应蛋白反应。
DOI:
10.1093/cid/ciy299
发表时间:
2018
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
作者:
[Uhde,Melanie, Indart,Alyssa, Fallon,BrianA, Wormser,GaryP, Marques,AdrianaR, Vernon,SuzanneD, Alaedini,Armin]
通讯作者:
Alaedini,Armin
Intestinal Immune Response in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
-
批准号:9021859
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2016
-
负责人:ARMIN ALAEDINI
-
依托单位:
Immunologic mechanisms in post-Lyme disease syndrome
-
批准号:8309627
-
项目类别:
-
资助金额:$36.0万
-
财政年份:2011
-
负责人:ARMIN ALAEDINI
-
依托单位:
Immune reactivity to synapsin in the neuropathy and ataxia of celiac disease
-
批准号:7209223
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2007
-
负责人:ARMIN ALAEDINI
-
依托单位:
Immune reactivity to synapsin in the neuropathy and ataxia of celiac disease
-
批准号:7364150
-
项目类别:
-
资助金额:$18.38万
-
财政年份:2007
-
负责人:ARMIN ALAEDINI
-
依托单位:
OspA and autoimmunity in chronic Lyme disease
-
批准号:7137519
-
项目类别:
-
资助金额:$26.66万
-
财政年份:2006
-
负责人:ARMIN ALAEDINI
-
依托单位:
OspA and autoimmunity in chronic Lyme disease
-
批准号:7267923
-
项目类别:
-
资助金额:$20.39万
-
财政年份:2006
-
负责人:ARMIN ALAEDINI
-
依托单位:
Molecular Biomarkers for Identification of Disease Stage in Lyme Borreliosis
-
批准号:8566212
-
项目类别:
-
资助金额:$15.5万
-
财政年份:--
-
负责人:ARMIN ALAEDINI
-
依托单位:
Molecular Biomarkers for Identification of Disease Stage in Lyme Borreliosis
-
批准号:8566251
-
项目类别:
-
资助金额:$29.56万
-
财政年份:--
-
负责人:ARMIN ALAEDINI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: